Ypsomed AG

Ypsomed AG is a Swiss medical technology company based in Burgdorf, Switzerland, founded in 1984. The company specializes in the design, development, manufacturing, and sale of injection and infusion systems, primarily for diabetes care and other chronic conditions. Ypsomed operates in two main segments: Delivery Devices and Diabetes Direct Business. The Delivery Devices segment focuses on developing pen systems, autoinjectors, and infusion sets, which are sold globally to pharmaceutical and biotech companies. The Diabetes Direct Business markets devices directly to patients and healthcare providers, offering products like insulin pumps and self-monitoring blood glucose devices. Ypsomed is committed to innovation, recently launching smart insulin pens that incorporate digital technologies to enhance patient adherence and monitoring. The company collaborates with digital health firms to create integrated solutions for pharmaceutical customers. With around 2,200 employees and operations in Switzerland, Europe, and North America, Ypsomed reported revenues of approximately $619 million in 2023. The company is publicly traded on the Swiss Stock Exchange under the ticker YPSN and is recognized for its leadership in self-medication technology, particularly in diabetes care.